Akorn-Strides wins FDA approval for two generic antibiotics
Akorn-Strides is a joint venture that was formed in 2004 by Akorn and Strides Arcolab. The primary mission for the joint venture is to develop liquid, lyophilized and
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.